Healthcare Industry News: DFB Pharmaceuticals
News Release - March 29, 2007
Michael Steadman Named DFB Branded Pharmaceuticals Group President, COOFORT WORTH, Texas, March 29 (HSMN NewsFeed) -- H. Paul Dorman, Chairman and Chief Executive Officer of Fort Worth-based DFB Pharmaceuticals, Inc., has selected Michael E. Steadman to lead DFB Branded Pharmaceuticals, a new segment of the company that encompasses what were formerly four affiliate divisions: HEALTHPOINT®, Ltd., Tissue Management; Coria Laboratories, Ltd.; HEALTHPOINT International; and HEALTHPOINT Surgical.
DFB Branded Pharmaceuticals is one of three DFB business segments. The other two are DFB Pharmaceutical Services, represented by DPT Laboratories, Ltd. (San Antonio, Texas, and Lakewood, NJ) and DFB Biotechnology, represented by Phyton Biotech, Inc. (Princeton, NJ, and Ahrensburg, Germany).
As DFB Branded Pharmaceuticals Group President and Chief Operating Officer, Mr. Steadman will manage all operations of the enterprise.
"Michael has been an indispensable member of the DFB leadership team since HEALTHPOINT's inaugural year," said Mr. Dorman. "He has taken ownership of our company's destiny and guides us along our path to success. He will no doubt replicate his exemplary leadership for Branded Pharmaceuticals during this next stage of our growth."
Mr. Steadman, a 15-year veteran of DFB, was most recently President of HEALTHPOINT Tissue Management. His ascent on DFB's corporate ladder began in 1992 when he joined the original HEALTHPOINT®, Ltd., as director of sales during the company's first year of business, establishing the inaugural field sales organization for HEALTHPOINT's first branded business --- Tissue Management. Since then, Mr. Steadman has become a strategic leader, guiding HEALTHPOINT to become one of the fastest growing, largest wound care companies in the U.S., according to DFB officials.
With the reorganization, the Tissue Management and Surgical divisions are united under one HEALTHPOINT umbrella forming DFB's largest branded business, which markets proprietary over-the-counter, prescription, and biopharmaceutical products for skin and soft tissue indications. Rob Bancroft is General Manager of HEALTHPOINT.
As Group President and COO of DFB Branded Pharmaceuticals, Mr. Steadman will work directly with Mr. Bancroft and other top division leadership for DFB Branded Pharmaceuticals: Steve Clark, President of Coria and Jay Nisbet, Senior Director of International. Mr. Steadman will also work closely alongside and guide DFB Branded Pharmaceutical leaders Duncan Aust, PhD, Senior Vice President, Research and Development; Mike Bernstein, MPH, Vice President, Regulatory Affairs; Herbert Slade, MD, Chief Medical Officer; Mike Carmena, Senior Director, Finance and Administration; Gerry Keith, Deputy General Counsel; and Mary Beth Dudley, Senior Director, Human Resources.
"We are dedicated to successfully aligning our branded pharmaceuticals businesses," said Mr. Steadman. "It is an honor to work with and learn from Paul Dorman and be inspired by his long-term vision. I look forward to realizing and executing this bold vision."
Michael Steadman began his career with Carrington Laboratories in 1987 after graduating from Eastern Illinois University with a Bachelor of Arts degree in marketing. Following his first four years at HEALTHPOINT, Mr. Steadman was promoted from Director of Sales to Vice President of Sales, quickly increasing company net income, doubling the sales organization and growing sales four fold. By 1999, he became Senior Vice President, Sales and Marketing while leading an aggressive acquisition strategy. Under his leadership, the Tissue Management team launched its largest pharmaceutical brand. In 2002, Mr. Steadman was promoted to President of HEALTHPOINT. In that role, Mr. Steadman chaired DFB's strategic planning process; led the acquisition of SANTYL®, a debriding agent for wounds; and secured a license for a Phase III drug from Barrier Therapeutics.
Now, as Group President and COO of DFB Branded Pharmaceuticals, Mr. Steadman also continues to serve as Chairman of the Board, DFB Biotech of Curacao N.V. and Senior Vice President, DFB Pharmaceuticals, Inc.
As a complement to his positions within the DFB companies, Mr. Steadman serves on the Board of Directors for the Wound Healing Society Foundation. He is also active in community efforts in the North Texas area. Mr. Steadman is Chair for the Gladney Center for Adoption's Domestic Services committee as well as Secretary on the organization's Board of Directors, and is a member of the Gladney executive committee. Additionally, Mr. Steadman has served many years as a coach for the Fort Worth Youth Soccer Association.
DFB Pharmaceuticals, Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide. DFB's business structure is organized by segments: Branded Pharmaceuticals, Biotechnology, and Pharmaceutical Services. The Branded Pharmaceuticals segment includes HEALTHPOINT, Ltd., active in the research, development, and marketing of branded pharmaceuticals, over-the-counter drugs, and biotech drugs for tissue management and surgical indications since 1992; and Coria Laboratories, Ltd., focusing on dermatology and treatments of diseases that affect the skin, hair, and nails. Pharmaceutical Services includes DPT Laboratories, Ltd., a Contract Development and Manufacturing Organization (CDMO) and industry source for semi-solid and liquid development and manufacturing services for the world's leading pharmaceutical, biotechnology, and healthcare companies. The Biotechnology segment encompasses Phyton Biotech, Inc., whose proprietary plant cell culture technology platform is used to develop and manufacture products with applications in the pharmaceutical and biotech industries; and Phyton's German subsidiary, Phyton GmbH, which operates the world's largest commercial cGMP manufacturing facility for plant cell fermentation. DFB is on the web at http://www.dfb.com .
Source: DFB Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.